Previous study have demonstrated that reduction of BRCA1 in breast cancer cell can increase the sensitivity of cisplatin and also lead to the resistance of anti-microtubule drugs (such as paclitaxel and vincristine) (Lafarge et al., 2001). This evidence concerns the gene BRCA1 and breast carcinoma.